These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 2986929)

  • 21. Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey.
    Dykstra LA
    J Pharmacol Exp Ther; 1990 Jul; 254(1):245-52. PubMed ID: 2164093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 1993 Oct; 267(1):322-30. PubMed ID: 8229759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Full ยต-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
    van Niel JC; Schneider J; Tzschentke TM
    Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nalbuphine's reversal of hypovolemic shock in the anesthetized rat.
    McKenzie JE; Anselmo DM; Muldoon SM
    Circ Shock; 1985; 17(1):21-33. PubMed ID: 2996801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of effect of morphine-like analgesics on transmurally stimulated guinea-pig ileum.
    Fennessy MR; Heimans RL; Rand MJ
    Br J Pharmacol; 1969 Oct; 37(2):436-49. PubMed ID: 5348430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-choice discrimination in pigeons is based on relative efficacy differences among opioids.
    Walker EA; Picker MJ; Dykstra LA
    Psychopharmacology (Berl); 2001 Jun; 155(4):389-96. PubMed ID: 11441428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nalbuphine, a mixed kappa 1 and kappa 3 analgesic in mice.
    Pick CG; Paul D; Pasternak GW
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1044-50. PubMed ID: 1326621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-administration of nalbuphine attenuates the morphine-induced anxiety and dopaminergic alterations in morphine-withdrawn rats.
    Raghav R; Jain R; Jacob TG; Dhawan A; Roy TS
    Psychopharmacology (Berl); 2021 Apr; 238(4):1193-1211. PubMed ID: 33655408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
    Cowan A; Lewis JW; Macfarlane IR
    Br J Pharmacol; 1977 Aug; 60(4):537-45. PubMed ID: 409448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The enflurane sparing effect of morphine, butorphanol, and nalbuphine.
    Murphy MR; Hug CC
    Anesthesiology; 1982 Dec; 57(6):489-92. PubMed ID: 7149306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NOP receptor mediates anti-analgesia induced by agonist-antagonist opioids.
    Gear RW; Bogen O; Ferrari LF; Green PG; Levine JD
    Neuroscience; 2014 Jan; 257():139-48. PubMed ID: 24188792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The analgetic effects of an intrathecally administered partial opiate agonist, nalbuphine hydrochloride.
    Schmauss C; Doherty C; Yaksh TL
    Eur J Pharmacol; 1982 Dec; 86(1):1-7. PubMed ID: 6897635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonist/antagonist properties of nalbuphine, butorphanol and (-)-pentazocine in male vs. female rats.
    Craft RM; McNiel DM
    Pharmacol Biochem Behav; 2003 Apr; 75(1):235-45. PubMed ID: 12759132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the analgesic effect of intramuscular nalbuphine and morphine in patients with postoperative pain.
    Beaver WT; Feise GA
    J Pharmacol Exp Ther; 1978 Feb; 204(2):487-96. PubMed ID: 340643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal pharmacology of Wy-16,225, a new analgesic agent.
    Malis JL; Rosenthale ME; Gluckman MI
    J Pharmacol Exp Ther; 1975 Sep; 194(3):488-98. PubMed ID: 808600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1979 Feb; 17(2):81-110. PubMed ID: 378645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute and chronic morphine administration: effects of mixed-action opioids in rats and squirrel monkeys responding under a schedule of food presentation.
    Oliveto AH; Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1991 Apr; 257(1):8-18. PubMed ID: 1850479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Action of opioid agonist-antagonist drugs on the pupil and nociceptive responses in mice.
    Stav A; Rabinowitz R; Korczyn AD
    J Anesth; 1992 Oct; 6(4):439-45. PubMed ID: 15278517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose ratio is important in maximizing naloxone enhancement of nalbuphine analgesia in humans.
    Gear RW; Gordon NC; Miaskowski C; Paul SM; Heller PH; Levine JD
    Neurosci Lett; 2003 Nov; 351(1):5-8. PubMed ID: 14550900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.